Its sold both as a cosmetic ingredient and as a research compound, and after an April 2026 FDA Federal Register notice it moved into the second wave of the agencys compounding (PCAC) review, with a decision expected before February 2027
This means the process might require as much time
Ideal candidates for leading with NAD+: Patients over 40 experiencing persistent fatigue that does not resolve with sleep or lifestyle changes Individuals with metabolic syndrome, insulin resistance, or difficulty managing weight despite dietary effort Patients recovering from substance use, where NAD+ IV therapy has shown measurable benefit in reducing withdrawal symptoms and cravings High-performance athletes or executives seeking cognitive edge and faster physical recovery Patients with early neurodegenerative concerns who want evidence-supported mitochondrial support GHK-Cu Dosage and NAD+ Dosage: What Clinical Protocols Actually Use Dosing varies based on delivery route, patient body weight, and clinical goal
The IV LOUNGE CT Standard Discover the IV Lounge CT Standardwhere safety, expertise, and personalized care come first
What Equipment Is Required to Make Bac Water at Home